Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers.
about
Transforming Big Data into Cancer-Relevant Insight: An Initial, Multi-Tier Approach to Assess Reproducibility and Relevance.Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6Challenging a Misnomer? The Role of Inflammatory Pathways in Inflammatory Breast CancerHDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancersRationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor TherapeuticRuxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROSKnockdown of CMTM3 promotes metastasis of gastric cancer via the STAT3/Twist1/EMT signaling pathway.Transcriptional Network Architecture of Breast Cancer Molecular SubtypesSHP2, SOCS3 and PIAS3 Expression Patterns in Medulloblastomas: Relevance to STAT3 Activation and Resveratrol-Suppressed STAT3 Signaling.The recurrent architecture of tumour initiation, progression and drug sensitivity.An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis.Calprotectin and the Initiation and Progression of Head and Neck Cancer.Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.Quantitative assessment of protein activity in orphan tissues and single cells using the metaVIPER algorithm.Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.Tumor-derived mesenchymal-stem-cell-secreted IL-6 enhances resistance to cisplatin via the STAT3 pathway in breast cancer.
P2860
Q31113901-014AD5FA-94B3-44F3-A270-65982CE4A8E9Q33705487-56A464E3-AD35-4B13-AB36-391282471771Q33760216-C0BEA880-3966-43E5-9997-27C967D62FAFQ36354259-431E4666-3661-4059-8899-410973E64309Q36995729-B018C048-D77F-494E-BAE8-FC7EB7942933Q37109457-4385074F-E6F3-4011-A5D3-C1BBEBB46ABDQ37301868-47975152-4137-47C9-AA0E-9D09A9C2773DQ37428430-7B91917A-ACB1-4DBC-96E4-A9EA29F4B6F8Q37628299-62A0533F-6463-44FA-9921-38BBB31E7246Q39039006-D8776354-0096-4EE4-BE3D-A77DA0C59752Q47945450-F407E5A6-30F7-46E2-AD96-7C0CE1995E34Q50004471-8220EA34-7F2F-4881-B123-CBBDEA02482FQ51072153-3E56A9E7-E11A-461F-AC5D-0165638BB28AQ52584634-B1C32291-2B32-4D4B-92E1-C31200CDF70CQ52671240-CF9D8B82-C135-4ABA-93BD-5EBB9364948BQ54982591-0F54D509-D3AB-4A71-B190-4E79A5A3B88B
P2860
Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Inhibition of the autocrine IL ...... for HR-/HER2+ breast cancers.
@ast
Inhibition of the autocrine IL ...... for HR-/HER2+ breast cancers.
@en
type
label
Inhibition of the autocrine IL ...... for HR-/HER2+ breast cancers.
@ast
Inhibition of the autocrine IL ...... for HR-/HER2+ breast cancers.
@en
prefLabel
Inhibition of the autocrine IL ...... for HR-/HER2+ breast cancers.
@ast
Inhibition of the autocrine IL ...... for HR-/HER2+ breast cancers.
@en
P2093
P2860
P50
P356
P1433
P1476
Inhibition of the autocrine IL ...... for HR-/HER2+ breast cancers.
@en
P2093
Ana Collazo-Lorduy
Andrea Califano
Eva M Murga-Penas
Jose M Silva
Kevin Kalinsky
Laura P Saucedo-Cuevas
Mariano Alvarez
Matthew Maurer
Mireia Castillo-Martin
P2860
P304
P356
10.1101/GAD.262642.115
P577
2015-07-30T00:00:00Z